Workflow Services, a US-based platform to enable pharmacist-led clinical services, announced on Tuesday the successful completion of a one-year pilot and a nationwide expansion of its Colorectal Cancer Screening Education Program.
The aim of this initiative is to educate patients about the significance of colorectal cancer screening in the pharmacy setting. The program is intended to bridge the gap in preventive care because of the community pharmacy's unique position as many Americans' most accessible, trusted and frequently visited healthcare provider. In the pilot, 92% of the participating pharmacists reported increased proficiency in their ability to educate patients about the effect of colorectal cancer screening.
Following the pilot program's success, pharmacies across the country will now be able to use the Workflow Services platform to combine colorectal cancer screening education into their patient encounters.
Kevin Houlihan, Workflow Services president and CEO, said: "The data we collected in the pilot shows that we are unlocking a new, impactful healthcare channel. Access is one of the major challenges currently confronting the American healthcare system. And we've seen that by providing pharmacists with the right tools and guardrails in a platform like Workflow Services, we can make a real difference in closing care gaps and driving health outcomes."
CytoSite Bio signs collaboration agreement with Lantheus Holdings
Innate Pharma's IPH4502 to be featured at AACR 2025 Annual Meeting
Rafael Holdings completes merger with Cyclo Therapeutics, focuses on lead asset Trappsol Cyclo
Privo Technologies launches BeneVet Oncology for animal health
Actinium Pharmaceuticals signs Ac-225 radioisotope agreement with Eckert & Ziegler
Anixa Biosciences secures US patent allowance for ovarian cancer vaccine
Everest Medicines' EVM14 IND application receives US FDA approval
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab
Johnson & Johnson reports breakthrough overall survival data for EGFR-mutated lung cancer treatment
Black Diamond Therapeutics and Servier agree global licensing deal for BDTX-4933
Health Canada approves KEYTRUDA for advanced or recurrent endometrial carcinoma
Medivir secures European patent for fostrox and lenvatinib combination in liver cancer treatment
Workflow Services completes one-year pilot and expands Colorectal Cancer Screening Education Program